Skip to main content

Pain News (Page 4)

Women in Military More Likely to Suffer Chronic Pain During Wartime

MONDAY, July 8, 2024 – Wartime appears to increase the risk of chronic pain for military women, a new study suggests. Active-duty servicewomen who served between 2006 and 2013 – a period of h...

Just a Few Surgeries Make Up Most Post-Op Opioid Prescriptions

WEDNESDAY, July 3, 2024 – Opioid addiction often starts with a prescription for post-surgery pain relief, and two new studies identify a handful of procedures that account for large shares of those...

Ulcerative Hunner Lesions Can Help Characterize Bladder Pain, Infection

TUESDAY, July 2, 2024 – Distinct phenotypic and urine biological characteristics are seen for patients with interstitial cystitis/bladder pain syndrome (IC/BPS) with a history of ulcerative Hunner...

Positive Family Relationships May Protect Against Pain in Older Adults

FRIDAY, June 14, 2024 – Family support may protect against pain incidence and persistence among aging African Americans, according to a study published online May 20 in the Journals of Gerontology ...

What Can Cause Stomach Pain in Kids?

TUESDAY, May 21, 2024 – Many kids can get an occasional upset tummy, but what if your child's stomachaches are more persistent? Dr. David Ziring, associate director of the Pediatric Inflammatory...

FDA Medwatch Alert: FDA Warns Consumers to Avoid Certain Topical Pain Relief Products Due to Potential for Dangerous Health Effects

March 26, 2024 – The U.S. Food and Drug Administration is warning consumers not to use certain over-the-counter analgesic (pain relief) products that are marketed for topical use to relieve pain...

Vertex Announces Statistically Significant and Clinically Meaningful Results From Two Phase 2 Proof-of-Concept Studies of VX-548 for the Treatment of Acute Pain

Treatment with the NaV1.8 inhibitor VX-548 met the primary endpoint in both Phase 2 proof-of-concept acute pain studies following abdominoplasty or bunionectomy surgery VX-548 was generally well...

Vertex Advances VX-548 in Acute and Neuropathic Pain

VX-548 advances into pivotal development for people with acute pain; Phase 3 program to initiate in Q4 2022 Phase 2 dose-ranging trial in neuropathic pain expected to initiate by year end...

Vertex Announces Publication of VX-548 Positive Phase 2, Proof-of-Concept Results in New England Journal of Medicine

First published manuscript of VX-548 preclinical and clinical trial results in a peer-reviewed journal BOSTON--(BUSINESS WIRE)--Aug. 3, 2023-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX)...

Vertex Announces Positive Results From the VX-548 Phase 3 Program for the Treatment of Moderate-to-Severe Acute Pain

BOSTON--Jan. 30, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results from its Phase 3 program for the selective NaV1.8 inhibitor, VX-548, in the treatment of...

Pacira Announces FDA Approval of Expanded Exparel Label to Include Two Additional Nerve Block Indications

Exparel is the only FDA-approved single-dose regional analgesic to safely demonstrate four days of superiority versus bupivacaine in two clinical studies — New indications for use as an adductor c...

Caldolor Now FDA Approved for Treatment of Fever & Pain in Infants

NASHVILLE, Tenn., May 15, 2023 /PRNewswire/ – Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has...

FDA Medwatch Alert: Voluntary Recall of Certain Family Dollar Over-the-Counter Products

July 21, 2022 – Family Dollar is initiating a voluntary retail level product recall of certain products regulated by the U.S. Food and Drug Administration (FDA) that were stored and inadvertently...

FDA Approves Seglentis (celecoxib and tramadol hydrochloride) for the Management of Acute Pain

October 18, 2021 – The U.S. Food and Drug Administration (FDA) approved Seglentis (celecoxib and tramadol hydrochloride), a proprietary product developed by Esteve Pharmaceuticals' R&D team. It is...

FDA Approves Qdolo (tramadol hydrochloride) Oral Solution for the Management of Severe Pain

ATHENS, Ga., Sept. 8, 2020 /PRNewswire/ – Athena Bioscience, LLC, a specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has approved Qdolo™ (tramadol h...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Chronic Pain, Back Pain, Fibromyalgia, Headache, Muscle Pain, Neuralgia, Neck Pain, Chronic Myofascial Pain, Nocturnal Leg Cramps, Reflex Sympathetic Dystrophy Syndrome, Breakthrough Pain

Related drug support groups

gabapentin, tramadol, ibuprofen, oxycodone, Tylenol, hydrocodone, naproxen, acetaminophen, meloxicam, view more... amitriptyline, aspirin, Percocet, hydroxyzine, Norco, pregabalin, duloxetine, diclofenac, methadone, codeine, OxyContin, cyclobenzaprine, Vicodin, Celebrex, Aleve, fentanyl, Advil, Voltaren, morphine, clonidine, buprenorphine, Paracetamol Teva, nortriptyline, Paracetamol, Butrans, Motrin, cannabis, Dilaudid, Tylenol PM, indomethacin, Toradol, Ultram, Lortab, Vistaril, acetaminophen / hydrocodone, ketamine, Roxicodone, Arthritis Pain, ketorolac, Atarax, Percocet 10/325, hydromorphone, Nucynta, Belbuca